Quantum Pharmaceuticals has confirmed strong hits for Tuberculosis

According to the World Health Organization (WHO), 2 million people die from Tuberculosis each year. Despite progress in whiping out TB in other areas of the world, the WHO recently rated the rate of the disease in Africa as having reached alarming proportions with a growing number of TB cases and deaths linked to HIV.

Quantum Pharmaceuticals is pleased to announce that its project on Tuberculosis has yielded some strong hits and some surprising observations on the target, FtsZ (a cell division protein), as well as on some supposed ligands. An article on these discoveries will be published in the near future.

Quantum Pharmaceuticals screened 40,000 natural compounds yielding about 100 potential hits with with high bioactivity. This screening included the latest feature of Quantum Pharmaceuticals’ technology—protein flexibility, which is unique in the industry and crucial to obtaining accurate results. 60 compounds were tested against Mycobacterium smegmatis culture and two best hits with IC50 0.17 mg/l (0.3 mkmol/l) and about 10 one fold higher were found. In total, 27 compounds also showed activity against the Mycobacterium smegmatis culture.

This experiment yet again, underlines the great accuracy and potential of Quantum Pharmaceuticals technology.

In-vivo testing is planned for June at the Central Institute of Tuberculosis in Moscow. The project is expected to result in novel drug candidates against MDR (multi drug resistant) tuberculosis.

About Quantum Pharmaceuticals

Quantum Pharmaceuticals is a drug discovery company using its revolutionary proprietary computer-based technology for in-silico molecular modeling. Current drug discovery projects include AIDS, Cancer, Alzheimer’s disease, COPD, TB and Diabetes. Quantum Pharmaceuticals out-licenses the drug candidates at the preclinical stage to pharmaceutical companies and provides services based on its outstanding technology.